Compile Data Set for Download or QSAR
Report error Found 60 Enz. Inhib. hit(s) with all data for entry = 10135
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516028(US11053238, Compound 1a | US11053238, Compound 1b)
Affinity DataIC50: 1.70nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516275(US11053238, Compound 15b)
Affinity DataIC50: 1.80nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 1.90nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 2nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 2nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 2nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515904(4-(6-fluoro-1- methyl-1,2,3,4- tetrahydrobenzo[4,5...)
Affinity DataIC50: 2nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515904(4-(6-fluoro-1- methyl-1,2,3,4- tetrahydrobenzo[4,5...)
Affinity DataIC50: 2nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515923(US11053238, Compound 16b | US11053238, Example 16b)
Affinity DataIC50: 3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516028(US11053238, Compound 1a | US11053238, Compound 1b)
Affinity DataIC50: 3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515951(US11053238, Com. EX. 5)
Affinity DataIC50: 3nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515923(US11053238, Compound 16b | US11053238, Example 16b)
Affinity DataIC50: 3.40nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 4.10nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516050(US11053238, Compound 15a)
Affinity DataIC50: 6.70nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515983(US11053238, Com. EX. 6)
Affinity DataIC50: 7nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 10nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515983(US11053238, Com. EX. 6)
Affinity DataIC50: 14nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515951(US11053238, Com. EX. 5)
Affinity DataIC50: 17nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516065(US11053238, Compound 16a)
Affinity DataIC50: 17.6nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 22nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 22nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 22nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516275(US11053238, Compound 15b)
Affinity DataIC50: 23nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515904(4-(6-fluoro-1- methyl-1,2,3,4- tetrahydrobenzo[4,5...)
Affinity DataIC50: 23nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516028(US11053238, Compound 1a | US11053238, Compound 1b)
Affinity DataIC50: 23nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515904(4-(6-fluoro-1- methyl-1,2,3,4- tetrahydrobenzo[4,5...)
Affinity DataIC50: 23nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 31nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 39nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515923(US11053238, Compound 16b | US11053238, Example 16b)
Affinity DataIC50: 40nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515951(US11053238, Com. EX. 5)
Affinity DataIC50: 40nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515983(US11053238, Com. EX. 6)
Affinity DataIC50: 40nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515923(US11053238, Compound 16b | US11053238, Example 16b)
Affinity DataIC50: 45nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515986(US11053238, Com. EX. No. 7)
Affinity DataIC50: 57nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 90nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 108nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515986(US11053238, Com. EX. No. 7)
Affinity DataIC50: 110nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 111nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516028(US11053238, Compound 1a | US11053238, Compound 1b)
Affinity DataIC50: 121nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516050(US11053238, Compound 15a)
Affinity DataIC50: 230nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515923(US11053238, Compound 16b | US11053238, Example 16b)
Affinity DataIC50: 300nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/6(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516065(US11053238, Compound 16a)
Affinity DataIC50: 300nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515904(4-(6-fluoro-1- methyl-1,2,3,4- tetrahydrobenzo[4,5...)
Affinity DataIC50: 300nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-A2 [177-432]/Cyclin-dependent kinase 2(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 300nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM50110183(Abemaciclib | LY-2835219 | US10696678, Example LY2...)
Affinity DataIC50: 308nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516039(US11053238, Compound 2a | US11053238, Compound 2b)
Affinity DataIC50: 441nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 474nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515992(US11053238, Com. EX. No. 8)
Affinity DataIC50: 550nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516007(US11053238, Com. EX. No. 9)
Affinity DataIC50: 550nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D3(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM516019(US11053238, Com. EX. No. 10)
Affinity DataIC50: 550nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Betta Pharmaceuticals

US Patent
LigandPNGBDBM515905(N-(5-((4-ethylpiperazin- 1-yl)methyl) pyridin-2-yl...)
Affinity DataIC50: 572nMAssay Description:To demonstrate that the compounds exhibit affinity for CDK kinases (CDK2/CycA2, CDK4/CycD3, CDK6/cycD3), CDK kinase assays were performed.Reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
US Patent

Displayed 1 to 50 (of 60 total ) | Next | Last >>
Jump to: